HEAD AND NECK PARAGANGLIOMA-RETROSPECTIVE STUDY OF DISEASE SPECTRUM AND OUTCOME
Not Applicable
Completed
- Conditions
- Health Condition 1: C754- Malignant neoplasm of carotid body
- Registration Number
- CTRI/2020/06/025767
- Lead Sponsor
- Department of endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Including Head and neck paraganglioma(HNPGL) with/without sympathetic paraganglioma and pheochromocytoma
For PRRT therapy
-1) High-level uptake on Ga-68 DOTATATE scan( in terms of Krenning score more than 2 and low I-131, MIBG uptake
Exclusion Criteria
Only sPGL or only PCC
for PRRT Therapy
- 1) cytopenias in one or more cell lineages( hemoglobin <9g/dl, total leucocyte count <4000/microL),2)Functional status as determined by Karnofsky performance status less than 60% or the Eastern cooperative oncology group(ECOG) performance status score more than two.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To detect the most sensitive imaging modality for the detction head and neck paraganglioma including the metastatic lesions and to see for the effectiveness of PRRT therapyTimepoint: To detect the most sensitive imaging modality for the detction head and neck paraganglioma including the metastatic lesions and to see for the effectiveness of PRRT therapy
- Secondary Outcome Measures
Name Time Method To determine the safety profile of the PRRTTimepoint: Last clinical visit